LSTM’s health economists Professor Louis Niessen and Dr Jahangir Khan outline the importance for universal access to medicines in the control of neglected diseases, other major infections, and chronic diseases.
In an editorial in the journal The Lancet Professor Niessen and Dr Khan argue that strategies to make medicines more available and affordable are critical in increasing their use in low- and middle- income countries. There is a double burden of infectious and chronic diseases, while the awareness of the benefits of prevention and treatment has grown.
Their comment comes following the publication of the McMaster University-lead Prospective Urban Rural Epidemiology (PURE) study on the availability and costs of cardiovascular medicine across 18 countries. This landmark health economics study on the empirical costs of medicines with comparisons across both high- and low-income settings, shows that secondary prevention is unavailable and unaffordable in the surveyed 94,919 communities across the world. Professor Niessen and Dr Khan argue that its findings are important in the formulation of policies on universal health coverage and the mobilisation and use of resources in relation to NTDs, and infectious and chronic diseases.
They state that it is unlikely that surplus household income is available for prevention. Household expenditures relate to all major health events – including strokes, infarctions, neglected tropical diseases, major infections, injuries, and cancers. Many households become poor due to income loss from illness. Health safety nets such as insurance in advancing systems provide broader coverages. In fragile communities societal safety nets may cover all types of events as food shortages and disasters. Secondly, they explain that use of medicines is influenced by general awareness, health literacy, service quality, and the quality of workers. This is all important as increased availability may lead to misuse.
They acknowledge that universal access to medicine promotion has to address these multiple obstacles in the provision of appropriate care to communities. At national level, options for policy-makers are price control measures, price management of generic medicines and promotion of market entry through flexible TRIPS arrangements and licensing, and internal reference pricing of generic. An increase in international co-ordinated actions, such as mass production of low-cost antiretroviral drugs and the mass drug provision in the control of neglected tropical diseases is needed. Low cost treatments are possible for many conditions through mass production.
Read more: LSTM’s health economists call for strategies for universal access to medicines
The Latest on: Universal access to medicines
[google_news title=”” keyword=”Universal access to medicines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Universal access to medicines
- Caring Cross, ImmunoACT ink agreement to commercialize TriCAR-T cell immunotherapy for leukaemia and lymphomaon May 9, 2024 at 3:24 am
Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to ... cell therapy in India as part of our mission to further universal access ...
- Ottawa must expand pharmacare to include medicines for our deadliest diseaseson May 9, 2024 at 3:00 am
Millions of people in Canada live with cancer and heart disease and rely on prescription medicines to help keep them alive. Many cannot afford them.
- Universal Health Coverage - a Failure of Implementation or Strategy?on May 6, 2024 at 2:10 am
Halfway to the 2030 deadline for Universal Health Coverage, the world is severely off track. Nearly half of the global population lacks access to essential health services, with one in four facing ...
- WHO welcomes Spain’s Secretary of State for Health to discuss health prioritieson April 25, 2024 at 11:39 pm
WHO welcomed Mr Javier Padilla Bernáldez, Spain’s Secretary of State for Health and his delegation on 23 and 24 April 2024 to discuss joint global health priorities. Amongst others, Spain's focus is ...
- Pros and cons of universal health careon April 24, 2024 at 8:01 am
The NHS is an example of a single-payer system, funded by taxation. Other countries, such as France and Japan, provide universal health care through mandatory but low-cost health insurance schemes, in ...
- Food Is Medicine: The Road To Universal Coverageon April 8, 2024 at 5:00 pm
Collectively, these steps would make FIM a near universal health care benefit ... range of entities on strategies for improving access to food is medicine. The views express here are their own.
- Access to genomic medicine illustrates precision medicine's delicate futureon April 7, 2024 at 5:00 pm
As genomics and precision medicine advances open new avenues for ... if only people have access to them. New research has now delved into the challenge of accessing innovative care.
- U.S. Healthcare System Leaves Far Too Many People Underinsuredon January 1, 2024 at 6:11 am
I write about healthcare policy, with an emphasis on Rx drugs. Universal healthcare access remains an unrealized dream for the U.S. Addressing the problem of lack of (adequate) health insurance ...
- African Medicine Agency Crucial to Ensure Access to Quality Medicines in Continenton November 13, 2023 at 5:06 pm
which compromises the continent’s ability to provide affordable access to lifesaving, essential medicines in the global quest to advancing the right to health for all and to achieving Universal ...
- Medicines in Health Systems Working Toward Universal Health Coverage (Self-Paced)on May 11, 2023 at 1:13 pm
Many countries are reforming their health systems working toward universal health coverage (UHC). These reforms can be harnessed to increase equity in medicines access, affordability, and appropriate ...
via Bing News